Pfizer expands oncology and immunology pipeline strength New therapies show progress in clinical development Focus shifts ...

Pfizer Inc (NYSE:PFE) develops medicines and vaccines across multiple therapeutic areas, contributing to the S&P 500 ...

As pharmas like Eli Lilly and Roche bolster their biotech offerings, Pfizer is snuffing out its program designed to incubate new innovations from select companies, dubbed Pfizer Ignite. | As pharmas ...

Pfizer received its first obesity drug approval in China for Severwin, opening a new market for the company. The company also reported promising Phase 2 results for tilrekimig, a trispecific antibody ...

As its lead candidate advances into a late-stage trial for pulmonary arterial hypertension (PAH), Inhibikase Therapeutics has picked up a commercial leader with plenty of experience in the PAH space.

"Two things at once," the Kansas City Chiefs player repeats in the ad, as he promotes getting both shots in one sitting. Travis Kelce stars in a Pfizer commercial backing both the COVID-19 and flu ...

China has approved a new obesity treatment from Pfizer Inc., heightening competition in a market poised to become even more ...

Pfizer receives a tactical upgrade to Hold following its acquisition of Metsera, re-entering the obesity/GLP-1 market with promising clinical assets. The Metsera deal offers PFE strategic optionality ...

BridgeBio stock popped Tuesday on a notable shake-up in the patent battle surrounding Pfizer's rival drug, tafamidis.

Pfizer (NYSE:PFE) and Astellas Pharma reported positive pivotal Phase 3 results for PADCEV plus Keytruda in muscle invasive bladder cancer. The EV-304 (KEYNOTE-B15) trial showed a substantial ...